A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study

BACKGROUND: CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937) + pembrolizumab for metastatic/unresectable stage IIIB–IV melanoma. METHODS: Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3 weeks [Q3W]) and intravenous pembrolizumab 2 mg/kg Q3W from day 8. Primary endpoin...

Descripción completa

Detalles Bibliográficos
Autores principales: Silk, Ann W., O’Day, Steven J., Kaufman, Howard L., Bryan, Jennifer, Norrell, Jacqueline T., Imbergamo, Casey, Portal, Daniella, Zambrano-Acosta, Edwin, Palmeri, Marisa, Fein, Seymour, Wu, Cai, Guerreiro, Leslie, Medina, Daniel, Bommareddy, Praveen K., Zloza, Andrew, Fox, Bernard A., Ballesteros-Merino, Carmen, Ren, Yixin, Shafren, Darren, Grose, Mark, Vieth, Joshua A., Mehnert, Janice M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198910/
https://www.ncbi.nlm.nih.gov/pubmed/36445410
http://dx.doi.org/10.1007/s00262-022-03314-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198910/
https://www.ncbi.nlm.nih.gov/pubmed/36445410
http://dx.doi.org/10.1007/s00262-022-03314-1

Ejemplares similares